Sign inJoin waitlistJoin the waitlist

Oleg Gligich

Physician · Mount Sinai Medical Center of Florida, Inc

Credentials: · · · ·

History

Mount Sinai Medical Center of Florida, Inc
2020–Present

Hematology and Medical Oncology
Jacobi Medical Center
2014–2017
Albert Einstein College of Medicine of Yeshiva University
2011–2014
Ross University School of Medicine
2007–2011
Hunter College in Manhattan

Research

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3…
JAMA Oncology · 2023 · 399 citations
Signal transduction inhibitors in treatment of myelodysplastic syndromes
Review · Journal of Hematology & Oncology · 2013 · 45 citations
High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis
Journal of Biological Chemistry · 2013 · 34 citations

EJ
Erin Jou
3 papers · 2 as a fellow
Henny Billett
3 papers
RR
Radha Raghupathy
3 papers
Uriel Felsen
3 papers · 2 as a fellow
Amit Verma
2 papers
Mike Cusnir
2 papers
Sabarish Ayyappan
2 papers
AL
Alexandra Lyubimova
1 paper · 1 as a fellow
Andrew Artz
1 paper
Andrew Brenner
1 paper
Andrew Sloan
1 paper
Arnold Blaustein
1 paper

Clinical trials

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2032
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034